Pfizer Inc. Updates the Public on Clinical Research Programs in Relation to COVID-19

Pfizer Worldwide Research Development and Medical, has updated their website’s page dedicated to information regarding COVID-19 and how they are approaching current and planned clinical research programs. The Duchenne Muscular Dystrophy programs are exempt from their three week pause. Phase 1b remains on-going and the start-up activities will continue for the phase 3 study.

To view Pfizer’s website page with information regarding COVID-19, please click here.